Eagle Biosciences and AroCell are pleased to invite you to a
webinar on the application of the TK
210 (Thymidine Kinase 1) ELISA in the study of malignancies.
There are many biomarkers of tumor mass, but few serum
biomarkers of tumor proliferation, a key indicator when making prognoses
and choosing and monitoring therapy.
The assay of serum Thymidine Kinase 1 with the AroCell TK 210
ELISA has the potential to be such a biomarker. There is no cost for
this event.
When: March
23, 2017 | 11 am to 11:30 am EDT
Presenters:
- Staffan Eriksson, Professor in Medical and Physiological Chemistry, Swedish
University of Agricultural Sciences
- Martin
Shaw, Business Development Manager at AroCell.
Key points of the presentation will be:
- Thymidine
kinase 1 (TK1) is a well-known proliferation biomarker but most
current methods are based on enzyme activity methods and may
underestimate serum TK1 levels, particularly in subjects with solid
tumors
- The AroCell
TK 210 ELISA adds value to studies with existing tumor biomarkers
- Data will be
presented on the value of the AroCell TK 210 ELISA in the study of a
range of hematological and solid tumors.
Receive a white paper on the use of TK1 and the AroCell TK210 ELISA in studying solid tumors HERE
 About AroCell
AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer. |
